AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2690-1919/568
1International Research Center for Biological Sciences, Ministry of Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
2NanoGun Technology NGT, ZAC Les Portes de l’ Oise Rue Henri Becquerel (Plan) Voie 2 - Batiment B8 60230 Chambly, Paris, France.
3Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
4Research and Expertise Group, French Association for Medical Research Advancement (AFPREMED), 31100 Toulouse France.
5Zhejiang Huayi Nano Biotechnology Co., Ltd. Hangzhou, 311500, China.
6Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
7Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, 200032, Shanghai, China.
8Department of Oncology, Fudan University Shanghai Cancer Center, 200032, Shanghai, China.
9Department of Nuclear Medicine, Xin Hua Hospital. Shanghai Jiao Tong University, School of Medicine. Shanghai, 200082, China.
10Oncology Department of Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.
*Corresponding Author: Yong Gao, Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China and Guanghua Yang, International Research Center for Biological Sciences, Ministry of Science and Technology, Shanghai Ocean University
Citation: Weiyang JIN, H. Belhadj-Tahar, N. Sadeg, S. Morais, Jun Zhao, et al, (2025), Safety of [188RE]Re-Imdendrim in the Treatment of Tumor Indications, J Clinical Research and Reports, 21(1); DOI:10.31579/2690-1919/568
Copyright: © 2025, Yong Gao and Guanghua Yang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 03 September 2025 | Accepted: 11 September 2025 | Published: 17 September 2025
Keywords: autism spectrum disorder; cognitive epileptiform disintegration; evoked cognitive potentials; fractional anisotropy; diffusion tensor MR imaging; standardized psychiatric diagnostic methods
The detection of intraoperative stroke is paramount for enhancing patient outcomes during major vascular surgical procedures. Prior studies have demonstrated that alterations in cerebral blood flow (CBF) resulting from surgical interventions can be identified through a variety of neuromonitoring techniques, including electroencephalography, neurophysiological evoked potential assessments, transcranial Doppler ultrasound, and near-infrared spectroscopy. In this report, we present a case involving an open repair for type B aortic dissection that was complicated by extensive, multifocal cerebral infarctions. A notable intraoperative decline in the Patient State Index (PSI) and a concomitant rise in the Suppression Ratio (SR) were observed immediately following the transition of bypass modalities. This decline in PSI did not recover by the conclusion of the surgical procedure, despite only minor fluctuations in blood pressure and cerebral oximetry. Continuous monitoring of the PSI may facilitate the early detection and differentiation of intraoperative strokes, even in the absence of compromised CBF.
In 2022, the global incidence of cancer reached 20 million cases, with 9.7 million deaths. The escalating global burden of cancer warrants attention worldwide[1]. Thus far, curative resection remains the most effective treatment for tumors[2]. However, due to delayed diagnosis and patient factors such as age, frailty, and comorbidities, the proportion of patients eligible for surgical resection is not high[3-5]. Additionally, the recurrence rate after tumor resection remains high[6]. Conventional chemotherapy and radiotherapy have suboptimal efficacy[7-9]. In recent years, advancements in nuclear technology have led to the emergence of exciting radioactive drugs, which demonstrate high efficacy in cancer imaging and treatment. These drugs offer a promising therapeutic strategy for challenging-to-operate tumors and tumor resistance issues[10-12].
Early radioactive drugs, such as I-131 potassium iodide compounds (radioiodine therapy, RIT), have been extensively employed in clinical practice, with considerable success in the treatment of thyroid cancer[13-14]. I-131 is the active ingredient in RIT, which employs the specific uptake of iodine by thyroid cancer cells to achieve targeted radiotherapy for thyroid cancer[15]. Nevertheless, with a half-life of 8.05 days[16], I-131 necessitates a lengthy treatment cycle. The systemic radiation therapy feature of RIT may potentially result in damage to organs and tissues outside the thyroid[17].
[177Lu]Lu-PSMA-617, which has been designated as a breakthrough therapy by the FDA in recent years, is a small molecule radiolabeled with PSMA (prostate-specific membrane antigen)[18]. It is designed to target prostate cancer cells that express PSMA. The radiopharmaceutical delivers 177Lu to prostate cancer cells expressing PSMA, inducing apoptosis through β radiation, thereby achieving targeted radiotherapy[19]. However, [177Lu]Lu-PSMA-617 is primarily indicated for the treatment of PSMA-positive prostate cancer, with limited efficacy in PSMA-negative patients, The range of indications is relatively narrow[20].
Radioembolisation is a locally administered arterial route therapy that utilises tumor vascular proliferation to deliver high-dose radiation therapy. This method has been used in hepatocellular carcinoma (HCC) treatment[21-22]. Radioembolisation devices consist of 20-40μm beads, with yttrium-90 (90Y) integrated into a glass or resin. 90Y emits β rays with a physical half-life of 64 hours. Microspheres carrying [90Y] (20-40μm) are capable of killing tumor cells through embolisation, but cannot diffuse into other areas of the tumor. Consequently, in cases of a large tumor volume, other tumor regions remain untreated[23-26].
In this context, to address some of the current issues faced by radiopharmaceuticals, we have developed a liquid, non-embolic, in-situ tumor treatment method using fifth-generation dendritic polylysine (DGL) as a scaffold to transport nitroimidazole complexes chelated with rhenium-188 (188Re). By injecting [188Re]Re-ImDendrim directly into the tumor, utilizing the high affinity of nitroimidazole for hypoxic tumor cells, 188Re carried by [188Re]Re-ImDendrim is selectively absorbed by hypoxic tumor cells. Subsequently, the nano carrier DGL delivers 188Re throughout the entire tumor, emitting β rays to kill tumor cells.
This approach represents a departure from the conventional paradigm of single-indication nuclear medicine treatment, with the potential to address the treatment of all hypoxic solid tumors. It offers a new targeted anticancer drug for the in-situ treatment of primary and metastatic tumors.
Trial Oversight
The multi-center clinical trial of the new technology for targeted cancer therapy, "Nano Gun," is an Investigator-Initiated Trial (IIT) initiated by researchers and conducted in Shanghai, China. The trial design and baseline characteristics of patients were developed by the research committee. The trial was designed and overseen by a steering committee，and received funding support from the Science and Technology Commission of Shanghai Municipality, China (Project name: Multi-center clinical trial of the new technology "Nanogun" for targeted tumor treatment. Project number is: 19411951100). The funder had no role in the design or conduct of the trial, nor did they participate in data collection or analysis, manuscript writing, or the decision to submit for publication. The trial protocol has been approved by the ethics committees of Shanghai East Hospital, Xinhua Hospital, and Fudan University Shanghai Cancer Center in China, and is available on (the Supplementary Appendix1). The trial is conducted in accordance with the principles of the Helsinki Declaration. The authors are responsible for the accuracy and completeness of the data and analysis, as well as the fidelity of the trial and this report to the protocol.
Sample Population
From June 2023 to February 2024, all patients enrolled in the [188Re]Re-Im Dendrim trial were screened at Shanghai East Hospital, Fudan University Affiliated Cancer Hospital, Xinhua Hospital, and Shanghai Sixth People's Hospital in Shanghai, China. Eligible patients were males and females aged 18 years and older with histologically or cytologically confirmed malignant solid tumors, either primary hepatic or pulmonary malignancies, or metastatic malignancies to the liver or lungs, as determined by CT or MRI, with a single tumor diameter >1.0 cm. Patients who had previously failed standard treatment regimens (defined as standard first- or second-line chemotherapy ± targeted therapy) were eligible. These patients had an Eastern Cooperative Oncology Group performance status score of ≤2 and an expected survival of ≥12 weeks. Baseline assessments were conducted for all patients prior to treatment.
The decision to treat on compassionate grounds was made by an interdisciplinary tumor board; patients gave written informed consent. This retrospective analysis meets the criteria for retrospective studies of the local ethics committee.
Preparation of [188Re]Re-ImDendrim
[188Re]Re-ImDendrim is consists of three components: a therapeutic agent utilizing 188Re's β-radiation, an imidazolic ligand targeting cancer cells, and a nanovector (Dendrimer G5) facilitating localized bioavailability. (the Supplementary Appendix2)
188Re is rinsed and labeled in the GMP manufacturing Workshop of radiopharmaceuticals. In the production process, the 188Re rinsed from the tungsten-rhenium generator is mixed with the acid solution, following this, mixture is introduced into the reducing agent at 72°C for 20 minutes under carbon monoxide. The dendrimer's coupling with 188Re occurs followed as the content of vial "B" (ligand) is introduced into the mixture, and incubation at 72°C for one hour. Finally, the radiolabelling success is assessed by the radiopharmacist using TLC with radio detection to confirm a labeling percentage of approximately 85% or higher, with any unlabelled compound identified as free reduced Rhenium 188. If the radiolabeling is successful, the final product is inserted into the sealed vial. The 188Re-ImDendrim vial is placed inside a radiation-shielded(the Supplementary Appendix 3).
The administration of the [188Re]Re-ImDendrim drug was conducted via percutaneous puncture under CT navigation. To mitigate radiation exposure to medical personnel, radiation-proof syringes were utilized, and patients were required to wear lead clothing. For whole-body SPECT using [188Re]Re-ImDendrim, data acquisition started 60 minutes after treatment, Sequential SPECT scans were conducted at 1h, 6h, 24h, 48h, 72h, and 96h post-administration to assess the uptake and retention of [188Re]Re-ImDendrim within the tumor and its systemic distribution within the patient. Image reconstruction and image analysis were performed using software provided by the Siemens. (Model: Siemens healthineers Symbia Intevo ® 16).
Throughout the course of clinical trials, surveillance was conducted to monitor and document adverse events (AEs) and serious adverse events (SAEs). The Eastern Cooperative Oncology Group Score (ECOG) Performance Status was assessed prior to each treatment session to gauge the patient's functional status. Each patient enrolled in the study received either all available medications or lacked alternative treatment options for their particularly challenging medical condition.
Statistical Analysis
Safety was assessed through descriptive analysis. Statistical analysis was performed using SPSS (IBM SPSS Statistics 22.0).
Demographic and clinical characteristics
A cohort of 51 patients were screened for participation in the study at Shanghai East Hospital, Fudan University Affiliated Cancer Hospital, and Shanghai Sixth People's Hospital in Shanghai China. 42 patients were successfully screened and enrolled, while the remaining 9 patients failed to be screened for the following reasons: no appropriate treatment lesions (4 cases), ineligible examination results (4 cases), and withdrawal of informed consent by family members (1 case). Among the 42 treated patients, 4 patients were lost to follow-up and returned to their local hospitals for treatment, and 2 patients refused subsequent treatment, resulting in a total of 42 patients included in the intention-to-treat (mITT) population analysis. This group of 36 patients underwent safety analysis (Figure 1). The ECOG score of these patients did not exceed 2 points, with only one case exhibiting an ECOG score of 3. 83.3% of patients had experienced treatment failure with prior standard protocols (defined as third line or above of chemotherapy±targeted therapy). Among the 36 cases of efficacy analysis, the treatment target lesions were mainly liver and lung tumors, accounting for 83.3% of the population. The median age was 59 years, with an age range of 26-78 years，74% of patients are male (Table 1). Baseline assessments were conducted for all patients prior to treatment.
Figure 1: Flowchart of investigations study of 188Re –ImDendrim
| Patient No. | Age, y | Gender | Primary tumor | Treatment lesion | ECOG Performance Status |
| 1 | 60 | Female | Colon cancer | Lung | 1 |
| 2 | 58 | Male | hepatic carcinoma | liver | 1 |
| 3 | 78 | Male | Lung cancer | Lung | 2 |
| 4 | 68 | Male | Gastric cancer | liver | 1 |
| 5 | 69 | Male | Gastric cancer | Inguinal lymph node | 1 |
| 6 | 62 | Male | Rectal cancer | Lung | 2 |
| 7 | 52 | Female | Lung cancer | adrenal gland | 1 |
| 8 | 36 | Male | osteosarcoma | Iliac soft tissue | 1 |
| 9 | 43 | Male | Colon cancer | liver | 1 |
| 10 | 75 | Female | Intrahepatic cholangiocarcinoma | liver | 1 |
| 11 | 70 | Male | Colon cancer | Lung | 1 |
| 12 | 58 | Female | ampulla cancer | liver | 1 |
| 13 | 26 | Male | Synovial sarcoma | chest wall | 1 |
| 14 | 65 | Female | Lung cancer | liver | 2 |
| 15 | 42 | Male | Colon cancer | liver | 1 |
| 16 | 67 | Male | Rectal cancer | liver | 1 |
| 17 | 50 | Male | Intrahepatic cholangiocarcinoma | Lung | 1 |
| 18 | 35 | Male | renal carcinoma | Left hip | 1 |
| 19 | 76 | Male | Lung cancer | Lung | 3 |
| 20 | 52 | Female | Lung cancer | adrenal gland | 1 |
| 21 | 61 | Male | Rectal cancer | liver | 1 |
| 22 | 53 | Female | Rectal cancer | Lung | 1 |
| 23 | 53 | Female | Rectal cancer | Lung | 1 |
| 24 | 69 | Male | Rectal cancer | Lung | 1 |
| 25 | 53 | Male | Lung cancer | Lung | 1 |
| 26 | 65 | Male | Rectal cancer | liver | 1 |
| 27 | 47 | Male | Gastric cancer | liver | 1 |
| 28 | 74 | Male | breast cancer | Lung | 1 |
| 29 | 74 | Male | Lung cancer | Lung | 1 |
| 30 | 59 | Male | hepatic carcinoma | liver | 1 |
| 31 | 70 | Male | Colon cancer | liver | 1 |
| 32 | 61 | Male | renal carcinoma | Lung | 1 |
| 33 | 55 | Female | Colon cancer | liver | 1 |
| 34 | 45 | Male | Rectal cancer | liver | 1 |
| 35 | 55 | Male | Colon cancer | liver | 1 |
| 36 | 74 | Female | Lung cancer | Lung | 2 |
Table 1: Patient Characteristics
[188Re]Re-ImDendrim production and quality inspection
Following the radiolabeling of the [188Re]Re-ImDendrim with 188Re via elution from a tungsten-rhenium generator in a GMP pharmaceutical factory, the labeling efficiency of the [188Re]Re-ImDendrim was evaluated using thin-layer chromatography (TLC). The results demonstrated a labeling efficiency of over 85% and the relative fluorescence value (RF) was found to be between 0.1 and 0.9. A comprehensive physical and chemical identification, as well as microbial testing, of [188Re]Re-ImDendrim was conducted in accordance with the established quality control manual. (Supplementary Data).
Treatment safety
All 36 efficacy-evaluated patients experienced at least one treatment-related adverse event (TRAE); the most common TRAEs were fatigue (47.2%, n=17), pain (44.4%, n=16), and nausea (30.6%, n=11), most of which were deemed related to invasive treatment. Grade 3 TRAEs occurred in 2 cases (5.6%), one of which was hematemesis during treatment, and postoperative gastroscopy confirmed it to be esophageal variceal bleeding, which was a past medical history of the patient. The other case was pneumothorax during follow-up after local treatment of pulmonary metastases, which improved following closed chest drainage and was related to the puncture process. No TRAEs of grade 4 or higher were observed in the population (Table 2).
The study indicates the absence of typical radionuclide therapy-related toxicities, such as hematologic toxicity, skin and mucosal damage, and organ function impairment. Some atypical manifestations associated with radiopharma treatment include fatigue, nausea, dizziness, etc., which typically resolve within 1-2 days of observation.
| NO. (%) (N=36) | |||
| TRAES | All grades | Grade 1-2 | Grade ≥3 |
| Fatigue | 17(47.2) | 17(47.2) | 0 |
| Pain | 16(44.4) | 16(44.4) | 0 |
| Nausea | 11(30.6) | 11(30.6) | 0 |
| dizziness | 9(25) | 9(25) | 0 |
| bleeding from different parts of the body | 8(22.2) | 7(19.4) | 1(2.8) |
| hypertension | 7(19.4) | 7(19.4) | 0 |
| pneumothorax | 4(11.1) | 3(8.3) | 1(2.8) |
| fever | 3(8.3) | 3(8.3) | 0 |
| hypotension | 2(5.6) | 2(5.6) | 0 |
| electrolyte imbalance | 2(5.6) | 2(5.6) | 0 |
| vomiting | 2(5.6) | 2(5.6) | 0 |
Table 2: Summary of treatment-related adverse events
Biodistribution and metabolism
The biodistribution of [188Re]Re-ImDendrim within the patient's body post-treatment was preliminarily assessed. Whole-body SPECT scans were conducted on the patients. Imaging was Captured at 1, 6, 24, 48, 72, and 96 hours post-administration, indicating predominant distribution within the treatment lesions with minimal imaging observed in other tissues. Given the renal excretion of 188Re, trace amounts accumulated in the intestines and bladder. At 1h, 6h, and 24h, small quantities of 188Re were detected in the intestines and bladder; however, by 48h, all nuclides were observed to be concentrated within the treatment lesions (Figure 2). This underscores the high uptake of [188Re] Re-ImDendrim by treatment lesions, while normal organs such as the brain, heart, liver, spleen, and muscle exhibited extremely low uptake rates.
Figure 2: Biodistribution of nuclide after [188Re] Re-ImDendrim treatment
Treatment efficacy
As of the data cutoff date, among the two patients with partial remission, one had lung metastasis from lung cancer, and despite disease progression in lung lesions during targeted treatment, consolidation was observed in the treated target lesion area following [188Re]Re-ImDendrim therapy. Subsequent 7-weeks follow-up demonstrated gradual lesion reduction, leading to partial remission (Figure 3A). The other patient with partial remission of the target lesion had liver metastasis from colorectal cancer. After standard first-line and second-line treatments, two liver lesions progressed compared to baseline. However, one lesion showed reduced size during follow-up at 2 months [188Re]Re-ImDendrim post-treatment, resulting in partial remissio (PR. Subsequent follow-up at 5 months revealed progression in other liver lesions and appearance of new lesions, while the target lesion remained stable (Figure 3B).
In other efficacy evaluation instances, significant reduction in blood supply was observed in target lesions treated with the [188Re] Re-ImDendrim, displaying low-density shadows within the tumor, indicating reduced tumor activity (Figure 3C).
Figure 3: Changes in lesions after [188Re]Re-ImDendrim treatment in typical cases. The red arrow indicates the injection site
The global attention being directed towards radiopharmaceuticals for cancer treatment is a noteworthy phenomenon. In this study, researchers completed the preparation and labelling of [188Re]Re-ImDendrim within two hours and injected it directly into the patient's tumor through in situ puncture. The procedure is straightforward and relatively rapid. Following the direct injection of [188Re]Re-ImDendrim into the tumor through puncture, the radioactive drug is almost concentrated in the target lesion throughout the entire energy delivery period. This is consistent with the results of our previous preclinical study[27]. The patients enrolled included a variety of solid tumors, including colorectal cancer, lung cancer, liver cancer, breast cancer, and soft tissue sarcoma. Following the administration of the [188Re]Re-ImDendrim treatment, the safety of the patients was evaluated, and no adverse event (AE) of grade 4 or higher was identified. The actual analysis of the adverse events (AEs) that occurred during treatment demonstrated that they were not related to the [188Re]Re-ImDendrim treatment.
Due to the half-life characteristics of radioactive drugs, it is important to shorten the preparation and injection time. QuiremSpheres™ is an excellent internal radiation therapy for liver cancer. It can be imaged not only by SPECT but also by MRI. However, the preparation process is too complicated, which limits its universal use[28-29]. [188Re]Re-ImDendrim uses a labelling kit to label within 2 hours. The steps are simple and suitable for wide application in nuclear medicine departments of different hospitals. [188Re] Rhenium is an isotope with a half-life of 16.9 h. Compared to [90Y] Yttrium, its short half-life ensures high dose rate delivery. At the same time, its β ray energy is higher, which is more conducive to disrupting the DNA chain of tumor cells[30]. Currently, the more commonly used 90Y-Spheres is used to deliver embolic internal radiotherapy for liver cancer via angiography. After treatment, whether it is bremsstrahlung SPECT/CT imaging or PET/CT imaging, its clinical application still faces many challenges[31-32]. The 188Re emits low-abundance γ rays of 155KeV (15%), which is very effective for imaging and dose calculation. It can provide additional diagnostic information, monitor and evaluate radiation dose in real time, and predict treatment effects, making it easy to achieve integrated diagnosis and treatment of cancer patients during the treatment process[33-34]. 188Re-complexed nitroimidazole has the ability to target hypoxic cells[35], so local treatment of liver cancer does not require vascular embolization and can be injected directly into the tumor. Solid tumors are highly hypoxic and the nitroimidazole property of targeting hypoxic cells opens up the possibility of [188Re]Re-ImDendrim for local treatment of other solid tumors. It exhibited good targeting in the various indications included in this study. SPECT showed that small amounts of [188Re]Re-ImDendrim were distributed in the intestine and bladder at 1h, 6h and 24h; at 48h all nuclides were found to concentrate in the treatment lesions. The treatment effect of 3 typical patients was demonstrated that the blood supply in the target lesions was significantly reduced, low density shadows in the tumor body and reduced tumor activity were observed, and the treatment effect was evident. In addition to the powerful β-radiation energy of the 188Re, the nanomaterial DGL also helps to enhance the efficacy of radioactive drugs. As a carrier of 188Re and nitroimidazole complex, DGL has been shown to have excellent cell transfection function and is widely used to deliver DNA and RNA to tumor cells and other cells[36-37]. The [188Re]Re-ImDendrim is injected into the tumor through puncture, and the nitroimidazole it carries targets hypoxic tumor cells. The nanocarrier DGL then exerts its delivery ability to deliver 188Re into the tumor cells, and uses the high-energy β rays of 188Re to interrupt the DNA chain of tumor cells, continuously killing the tumor. The cell transfection function of DGL not only delivers the nuclide 188Re deep into the tumor, resulting in the optimisation of the radiotoxicity effect of local treatment, which is beneficial for the killing of larger tumors, but also its transfection function may promote the targeting of [188Re]Re-ImDendrim and increase safety[38-39]. The distribution of 188Re in the body, as observed by SPECT imaging, may be related to the transfection of 188Re into tumor cells by DGL. Another notable feature of DGL is that it is non-immunogenic, which provides a favourable safety profile for [188Re]Re-ImDendrim[40]. No adverse event (AE) of grade ≥ 4 was observed in this clinical study, and the actual analysis of AEs that occurred during treatment demonstrated that they were not related to [188Re]Re-ImDendrim. 188Re is gaining increasing attention as a potential excellent medical nuclide. There have been numerous clinical studies on 188Re conducted globally[41-42]. Nitroimidazole has been extensively utilized as an antibacterial drug in clinical settings[43-44]. Consequently, the safety of the [188Re]Re-ImDendrim radiopharmaceutical employed in this project has been demonstrated to be consistent in both preclinical animal and clinical studies[27].
In this research we conducted a clinical trial of [188Re]Re-ImDendrim in 36 patients who had failed standard treatment protocols, assessing its biodistribution and safety in patients. It has been demonstrated to possess three key advantages:
The [188Re]Re-ImDendrim is directly injected into the tumor, where the 188Re complexes with the nitroimidazole ligand carrier, which is preferentially absorbed by hypoxic cells without embolisation.
The [188Re]Re-ImDendrim targets and remains at the site, thereby optimising the effects of radiation toxicity, while demonstrating good safety.
188Re is an isotope with a half-life of 16.9 hours, exhibiting greater β radiation energy compared to 90Y, with gamma radiation at 155-KeV (15%). This facilitates the seamless integration of diagnosis and treatment.
It should be noted that this study is subject to certain limitations. The clinical study protocol defines the patient flow, including the baseline assessment and dosimetry. However, the actual application process may vary according to the individual patient's condition. This study initially assesses the safety and distribution of [188Re]Re-ImDendrim. The principal challenges facing future studies include the definition and validation of the dose threshold for [188Re]Re-ImDendrim, the recruitment of a larger number of patients and the inclusion of additional tumor indications in order to further evaluate the safety and efficacy of the treatment. Of the 3 patients on high doses, 1 was PR and the rest were SD, and none had adverse reactions. This provides a basis for dose exploration in future clinical trials.
The [188Re]Re-ImDendrim represents a significant departure from the prevailing paradigm of single-indication treatment in targeted radionuclide therapy. The treatment process is straightforward, conducive to clinical treatment, safe, and effective. This new targeted anticancer drug will provide a new treatment option for in situ treatment of primary and metastatic tumors, as well as multiple tumor indications. It is a complement to the existing radioactive drug treatment of tumors. Clinical studies have demonstrated the safety and therapeutic potential of this promising local therapeutic radiopharmaceutical.
This work was supported by the Science and Technology Commission of Shanghai Municipality, China (Project name: Multi-center clinical trial of the new technology " Nanogun" for targeted tumor treatment. Project number is: 19411951100). No other potential conflict of interest relevant to this article was reported.
Informed consent was obtained for experimentation with human subjects
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."
I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.
To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.
"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".
I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.
Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.
We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.
My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.
To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina
Dear Jessica, and the super professional team of the ‘Clinical Cardiology and Cardiovascular Interventions’ I am sincerely grateful to the coordinated work of the journal team for the no problem with the submission of my manuscript: “Cardiometabolic Disorders in A Pregnant Woman with Severe Preeclampsia on the Background of Morbid Obesity (Case Report).” The review process by 5 experts was fast, and the comments were professional, which made it more specific and academic, and the process of publication and presentation of the article was excellent. I recommend that my colleagues publish articles in this journal, and I am interested in further scientific cooperation. Sincerely and best wishes, Dr. Oleg Golyanovskiy.
Dear Ashley Rosa, Editorial Coordinator of the journal - Psychology and Mental Health Care. " The process of obtaining publication of my article in the Psychology and Mental Health Journal was positive in all areas. The peer review process resulted in a number of valuable comments, the editorial process was collaborative and timely, and the quality of this journal has been quickly noticed, resulting in alternative journals contacting me to publish with them." Warm regards, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. I appreciate the journal (JCCI) editorial office support, the entire team leads were always ready to help, not only on technical front but also on thorough process. Also, I should thank dear reviewers’ attention to detail and creative approach to teach me and bring new insights by their comments. Surely, more discussions and introduction of other hemodynamic devices would provide better prevention and management of shock states. Your efforts and dedication in presenting educational materials in this journal are commendable. Best wishes from, Farahnaz Fallahian.
Dear Maria Emerson, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. I am delighted to have published our manuscript, "Acute Colonic Pseudo-Obstruction (ACPO): A rare but serious complication following caesarean section." I want to thank the editorial team, especially Maria Emerson, for their prompt review of the manuscript, quick responses to queries, and overall support. Yours sincerely Dr. Victor Olagundoye.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. Many thanks for publishing this manuscript after I lost confidence the editors were most helpful, more than other journals Best wishes from, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Agrippa Hilda, Editorial Coordinator, Journal of Neuroscience and Neurological Surgery. The entire process including article submission, review, revision, and publication was extremely easy. The journal editor was prompt and helpful, and the reviewers contributed to the quality of the paper. Thank you so much! Eric Nussbaum, MD
Dr Hala Al Shaikh This is to acknowledge that the peer review process for the article ’ A Novel Gnrh1 Gene Mutation in Four Omani Male Siblings, Presentation and Management ’ sent to the International Journal of Clinical Case Reports and Reviews was quick and smooth. The editorial office was prompt with easy communication.
Dear Erin Aust, Editorial Coordinator, Journal of General Medicine and Clinical Practice. We are pleased to share our experience with the “Journal of General Medicine and Clinical Practice”, following the successful publication of our article. The peer review process was thorough and constructive, helping to improve the clarity and quality of the manuscript. We are especially thankful to Ms. Erin Aust, the Editorial Coordinator, for her prompt communication and continuous support throughout the process. Her professionalism ensured a smooth and efficient publication experience. The journal upholds high editorial standards, and we highly recommend it to fellow researchers seeking a credible platform for their work. Best wishes By, Dr. Rakhi Mishra.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. The peer review process of the journal of Clinical Cardiology and Cardiovascular Interventions was excellent and fast, as was the support of the editorial office and the quality of the journal. Kind regards Walter F. Riesen Prof. Dr. Dr. h.c. Walter F. Riesen.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. Thank you for publishing our article, Exploring Clozapine's Efficacy in Managing Aggression: A Multiple Single-Case Study in Forensic Psychiatry in the international journal of clinical case reports and reviews. We found the peer review process very professional and efficient. The comments were constructive, and the whole process was efficient. On behalf of the co-authors, I would like to thank you for publishing this article. With regards, Dr. Jelle R. Lettinga.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, I would like to express my deep admiration for the exceptional professionalism demonstrated by your journal. I am thoroughly impressed by the speed of the editorial process, the substantive and insightful reviews, and the meticulous preparation of the manuscript for publication. Additionally, I greatly appreciate the courteous and immediate responses from your editorial office to all my inquiries. Best Regards, Dariusz Ziora
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation, Auctores Publishing LLC, We would like to thank the editorial team for the smooth and high-quality communication leading up to the publication of our article in the Journal of Neurodegeneration and Neurorehabilitation. The reviewers have extensive knowledge in the field, and their relevant questions helped to add value to our publication. Kind regards, Dr. Ravi Shrivastava.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, Auctores Publishing LLC, USA Office: +1-(302)-520-2644. I would like to express my sincere appreciation for the efficient and professional handling of my case report by the ‘Journal of Clinical Case Reports and Studies’. The peer review process was not only fast but also highly constructive—the reviewers’ comments were clear, relevant, and greatly helped me improve the quality and clarity of my manuscript. I also received excellent support from the editorial office throughout the process. Communication was smooth and timely, and I felt well guided at every stage, from submission to publication. The overall quality and rigor of the journal are truly commendable. I am pleased to have published my work with Journal of Clinical Case Reports and Studies, and I look forward to future opportunities for collaboration. Sincerely, Aline Tollet, UCLouvain.
Dear Ms. Mayra Duenas, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. “The International Journal of Clinical Case Reports and Reviews represented the “ideal house” to share with the research community a first experience with the use of the Simeox device for speech rehabilitation. High scientific reputation and attractive website communication were first determinants for the selection of this Journal, and the following submission process exceeded expectations: fast but highly professional peer review, great support by the editorial office, elegant graphic layout. Exactly what a dynamic research team - also composed by allied professionals - needs!" From, Chiara Beccaluva, PT - Italy.
Dear Maria Emerson, Editorial Coordinator, we have deeply appreciated the professionalism demonstrated by the International Journal of Clinical Case Reports and Reviews. The reviewers have extensive knowledge of our field and have been very efficient and fast in supporting the process. I am really looking forward to further collaboration. Thanks. Best regards, Dr. Claudio Ligresti
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation. “The peer review process was efficient and constructive, and the editorial office provided excellent communication and support throughout. The journal ensures scientific rigor and high editorial standards, while also offering a smooth and timely publication process. We sincerely appreciate the work of the editorial team in facilitating the dissemination of innovative approaches such as the Bonori Method.” Best regards, Dr. Matteo Bonori.
I recommend without hesitation submitting relevant papers on medical decision making to the International Journal of Clinical Case Reports and Reviews. I am very grateful to the editorial staff. Maria Emerson was a pleasure to communicate with. The time from submission to publication was an extremely short 3 weeks. The editorial staff submitted the paper to three reviewers. Two of the reviewers commented positively on the value of publishing the paper. The editorial staff quickly recognized the third reviewer’s comments as an unjust attempt to reject the paper. I revised the paper as recommended by the first two reviewers.
Dear Maria Emerson, Editorial Coordinator, Journal of Clinical Research and Reports. Thank you for publishing our case report: "Clinical Case of Effective Fetal Stem Cells Treatment in a Patient with Autism Spectrum Disorder" within the "Journal of Clinical Research and Reports" being submitted by the team of EmCell doctors from Kyiv, Ukraine. We much appreciate a professional and transparent peer-review process from Auctores. All research Doctors are so grateful to your Editorial Office and Auctores Publishing support! I amiably wish our article publication maintained a top quality of your International Scientific Journal. My best wishes for a prosperity of the Journal of Clinical Research and Reports. Hope our scientific relationship and cooperation will remain long lasting. Thank you very much indeed. Kind regards, Dr. Andriy Sinelnyk Cell Therapy Center EmCell
